Clinical Trial Results:
Phase IV, Open Label, Randomized, Clinical Trial to Evaluate the Reversibility of abacavir/lamivudine/dolutegravir CNS-Related Neurotoxicity After Switching to tenofovir alafenamide/emtricitabine/darunavir/cobicistat
Summary
|
|
EudraCT number |
2018-001158-82 |
Trial protocol |
ES |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Dec 2024
|
First version publication date |
27 Dec 2024
|
Other versions |
|
Summary report(s) |
PAPER GESIDA 10418 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.